Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
J Investig Med High Impact Case Rep ; 10: 23247096221111764, 2022.
Article in English | MEDLINE | ID: covidwho-1938262


Meningococcal pneumonia (MP) is a rare manifestation of meningococcal disease. The MP was first described in 1907 when Neisseria meningitidis (NM) isolates were identified in sputum samples obtained from soldiers with pneumonia. Preceding and concurrent viral infections constitute a major risk for MP. During the 1918-1919 influenza pandemic, a significant increase in MP cases were reported in patients with preceding influenza infection. Despite the end of the last H1N1 influenza pandemic in 2010, seasonal influenza infections still pose a risk for simultaneous MP. History appears to be repeating itself with concomitant bacterial and viral coinfection amid the current SARS-CoV-2 pandemic. Herein presented is a unique case of an elderly woman who presented with, to the best of our knowledge, the first reported case of possible concurrent SARS-CoV-2 and MP infections.

COVID-19 , Influenza A Virus, H1N1 Subtype , Influenza, Human , Meningococcal Infections , Neisseria meningitidis , Pneumonia , Aged , COVID-19/complications , Female , Humans , Influenza, Human/complications , Meningococcal Infections/complications , Meningococcal Infections/diagnosis , Meningococcal Infections/microbiology , Pneumonia/complications , SARS-CoV-2
J Infect ; 84(3): 289-296, 2022 03.
Article in English | MEDLINE | ID: covidwho-1536660


This review article incorporates information from the 4th Global Meningococcal Initiative summit meeting. Since the introduction of stringent COVID-19 infection control and lockdown measures globally in 2020, there has been an impact on IMD prevalence, surveillance, and vaccination compliance. Incidence rates and associated mortality fell across various regions during 2020. A reduction in vaccine uptake during 2020 remains a concern globally. In addition, several Neisseria meningitidis clonal complexes, particularly CC4821 and CC11, continue to exhibit resistance to antibiotics, with resistance to ciprofloxacin or beta-lactams mainly linked to modifications of gyrA or penA alleles, respectively. Beta-lactamase acquisition was also reported through horizontal gene transfer (blaROB-1) involving other bacterial species. Despite the challenges over the past year, progress has also been made on meningococcal vaccine development, with several pentavalent (serogroups ABCWY and ACWYX) vaccines currently being studied in late-stage clinical trial programmes.

COVID-19 , Meningococcal Infections , Meningococcal Vaccines , Neisseria meningitidis , COVID-19/prevention & control , Communicable Disease Control , Humans , Meningococcal Infections/epidemiology , Meningococcal Infections/microbiology , Meningococcal Infections/prevention & control , Meningococcal Vaccines/therapeutic use , Neisseria meningitidis/genetics , SARS-CoV-2 , Serogroup